Project Nightlight: Efficacy and System Acceptance of Dinner/Night vs. 24hr Closed Loop Control
Diabetes Mellitus, Type 1
About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 1 focused on measuring Closed-Loop Control (CLC), Sensor-Augmented Therapy (SAP), USS Virginia, Continuous Glucose Monitor (CGM), Insulin Pump, Artificial Pancreas (AP)
Eligibility Criteria
Inclusion Criteria:
- type 1 diabetes for at least one year
- using insulin for at least 1 year
- an insulin pump for at least 6 months
- willingness to switch to lispro (Humalog) or aspart (Novolog) if using glulisine (Apidra).
Exclusion Criteria:
- a medical condition or being been treated with medications that might interfere with the study
Sites / Locations
- University of Virginia Center for Diabetes Technology
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Group A
Group B
Order of intervention will be 1) SAP; 2) USS + SAP(d); 3) USS +CLC (d); 4) USS + SAP(d) SAP=sensor-augmented pump only USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control
Order of intervention will be 1)USS + SAP(d) ; 2)USS +CLC (d); 3) USS + SAP(d); 4) SAP SAP=sensor-augmented pump only USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control